Biogen Inc.

Biogen Inc.

251.84
USD
+70.78
(+39.09%)
2.35EPS
Feb 17Next Earn
Biogen Inc.
BCS:BIIB
(Santiago Stock Exchange)

Recent

price

251.84

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
18.69
20.83
23.18
29.26
41.05
46.66
52.42
57.73
65.66
76.85
83.56
73.65
70.02
67.97
66.46
67.51
69.88
Revenue per Share
3.98
5.09
5.8
7.86
12.42
15.37
16.95
11.94
21.62
31.47
24.86
10.44
20.97
8.02
11.21
8.83
2.36
Basic EPS, GAAP
5.75
6.27
6.83
-4.91
11.11
14.14
17.67
12.17
25.87
34.25
22.86
22.43
7.85
8.54
17.28
13.44
11.16
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
22.44
26.54
29.43
36.48
46.08
42.88
56.2
59.63
66.12
76.6
70.21
74.12
93.04
102.14
114.71
124.37
128.06
Book Value per Share
10.3
15.16
17.45
12.32
21.4
12
21.59
19.39
21.37
23.3
12.16
19.82
40.27
1.5
3.75
17.62
-9.82
Tangible Book Value per Share
252
242
238
237
236
231
218
213
205
187
161
149
145
145
146
147
147
Basic Weighted Avg Shares
4,716
5,049
5,516
6,932
9,703
10,764
11,449
12,274
13,453
14,378
13,445
10,982
10,173
9,836
9,676
9,891
10,297
Sales/Revenue/Turnover
33.27
35.25
33.33
35.92
40.37
46.59
49.39
45.05
44.61
48.93
33.07
25.57
28.52
18.79
23.57
24.96
17.55
Operating Margin (%)
356
359
366
532
688
600
683
1,081
651
465
457
488
518
495
673
780
882
Depreciation Expense
1,005
1,234
1,380
1,862
2,935
3,547
3,703
2,539
4,431
5,889
4,001
1,556
3,047
1,161
1,632
1,293
348
Net Income, GAAP
26.94
25.98
25.37
24.23
25.08
24.37
25.08
47.94
24.16
16.25
19.66
3.01
17.62
10.43
14.37
16.94
21.93
Effective Tax Rate (%)
21.31
24.45
25.02
26.86
30.25
32.95
32.34
20.69
32.93
40.96
29.76
14.17
29.95
11.81
16.87
13.07
3.37
Profit Margin (%)
1,490
2,063
1,587
1,427
2,317
4,123
5,312
4,505
4,346
3,518
3,145
3,558
6,518
3,425
1,928
5,625
3,686
Working Capital
1,066
1,061
687
592
580
6,522
6,513
5,935
5,937
4,872
7,828
6,604
6,614
7,188
4,882
6,577
7,401
LT Debt
5,449
6,427
6,964
8,621
10,814
9,375
12,129
12,598
13,032
13,339
10,686
10,960
13,388
14,799
16,716
18,257
18,922
Total Equity
12.96
18.03
17.75
21.76
28.39
26.73
22.06
14.85
23.73
30.4
19.02
14.74
17.2
6.75
7.9
5.86
1.81
Return on Invested Capital (%)
16.24
17.34
18.05
21.78
28.62
26.18
22.6
13.66
24.21
31.26
21.56
8.8
17.3
6.56
8.12
6.29
2.27
Return on Capital (%)
17.31
20.88
20.62
23.9
30.21
35.15
34.42
20.52
34.54
44.64
33.28
14.41
25.08
8.24
10.36
7.39
1.87
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
- -
800
400
LT Borrowings
6,289
7,290
7,292
LT Finance Leases
273
265
109
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
148
148
148
Market Capitalization
26,724
- -
- -

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
9,190
7,306
7,584
Cash, Cash Equivalents & STI
4,283
1,285
1,304
Accounts Receivable, Net
1,790
2,398
2,383
Inventories
1,949
2,384
2,224
Total Current Liabilities
2,999
3,917
3,898
Payables & Accruals
2,806
2,726
3,047
ST Debt
- -
800
400
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.66%
11.49%
9.22%
Free Cash Flow
8.37%
3.04%
-21.72%
Net Income, GAAP
4.09%
-1.48%
-20.79%
Sales/Revenue/Turnover
-0.48%
-5.68%
2.22%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,291
2,465
2,466
2,455
9,676
2025
2,431
2,646
2,535
2,279
9,891
2026
2,478
2,736
2,804
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.71
4.01
2.67
1.83
11.21
2025
1.65
4.33
3.18
-0.33
8.83
2026
2.17
0.66
-0.14
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Biogen Inc. (BIIB) discovers, develops, manufactures and commercializes therapies for neurological and neurodegenerative diseases, hemophilia, multiple sclerosis (MS), spinal muscular atrophy (SMA), lupus and rare diseases worldwide; core products include Tecfidera and Vumerity (dimethyl and diroximel fumarate) for MS, Avonex (interferon beta-1a), Plegridy (peginterferon beta-1a) and Tysabri (natalizumab) for relapsing MS, Spinraza for SMA, Leqembi for Alzheimer's disease, Skyclarys for Friedreich's ataxia and anti-CD20 therapies such as Rituxan and Gazyva for certain B-cell malignancies and autoimmune conditions. The company, founded in 1978 and headquartered in Cambridge, Massachusetts, operates in the United States, Europe, Asia and other international markets. Recent developments include the completion of its acquisition of Alcyone Therapeutics in November 2025 to bolster rare disease capabilities, a November 2025 collaboration with Dayra Therapeutics featuring a $50 million upfront payment for oral macrocyclic peptides targeting immunology, a February 2025 R&D funding agreement with Royalty Pharma worth up to $250 million for Phase 3 litifilimab in lupus, expansion of Leqembi with U.S. approval of the IQLIK subcutaneous formulation, an agreement to acquire Sage Therapeutics and groundbreaking in September 2025 for a new 580,000-square-foot headquarters at 75 Broadway set for completion in 2028 coinciding with the company's 50th anniversary.

Company News

  • TRIMTECH Therapeutics Enters Strategic Research Collaboration With Biogen to Advance Small Molecule Degraders for Neurodegenerative Disease

  • Which Healthcare ETF Is Best for the Long Term: State Street’s XPH or Invesco’s PBE?

  • Biogen Inc. $BIIB Stock: Allspring Global Investments Holdings LLC Boosts Holdings

  • LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Now Available in Japan for Patients with Early Alzheimer's Disease

  • Two Neighbors Will Start Leqembi, Listed at $28,270 a Year. One With Medigap Plan G Will Owe $0 in Coinsurance After the Part B Deductible, While the Other Will Owe 20% of Medicare-Approved Infusion Costs

  • Biogen Inc. $BIIB Stock: Alpha Family Trust Boosts Holdings

  • ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure

  • Biogen Provides Update on Private Payer Coverage for ZURZUVAE™ (zuranolone)

  • These Analysts Increase Their Forecasts On Biogen After Upbeat Q3 Results

  • Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026

  • Biogen Q3 Earnings Call Highlights

  • Biogen Inc. (BIIB) Q3 2026 Earnings Call Transcript

  • BIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View Tightened

  • Big Day for Econ Data, Hyperscaler Earnings

  • Biogen (BIIB) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

  • Biogen Inc. (BIIB) Tops Q3 Earnings and Revenue Estimates

  • Biogen Swings to Loss, Logs Higher Sales

  • Biogen Q3 Preview: Will Growth Products Drive an Earnings Beat?

  • Baron Health Care Fund: Q3 2026 New Positions And Exits

  • Biogen (BIIB) Surges 5.3%: Is This an Indication of Further Gains?